XETRA · Financial Services
Invest in Blue Cap stock from India
Indian and foreign residents can buy Blue Cap (B7E) shares directly through Paasa.
By Paasa · Updated
Blue Cap at a glance
- Price
- €15.50-€0.30 (1.90%)
- Market cap
- €69.54M
- Day range
- €15.20 – €15.90
- P/E
- 2.96
- Dividend yield
- 10.32%
- Volume
- 4.91K
- 1 month
- -5.49%
- 6 months
- -10.40%
- YTD
- -10.40%
- 1 year
- -26.19%
- 5 years
- -49.35%
Blue Cap statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €136.8M | €205.9M | €218.7M | €291.3M | €267.3M |
| Gross profit | €45.1M | €58.0M | €54.5M | €138.4M | €108.5M |
| Operating income | €2.5M | €1.5M | −€546.0K | €6.4M | €4.3M |
| Net income | €23.5M | €13.3M | −€17.8M | €12.2M | €5.2M |
| Earnings per share | €5.24 | €2.96 | −€4.02 | €2.78 | €1.24 |
| EBITDA | −€3.0M | €19.0M | €13.0M | €26.3M | €23.4M |
| Total assets | €207.2M | €216.0M | €243.9M | €330.4M | €285.9M |
| Total debt | €49.3M | €74.9M | €97.7M | €108.6M | €105.3M |
| Cash and short-term investments | €99.7M | €54.3M | €40.4M | €36.7M | €42.5M |
| Shareholders' equity | €110.8M | €95.1M | €83.8M | €103.7M | €93.1M |
| Operating cash flow | €10.8M | €13.0M | €19.6M | €14.1M | €10.3M |
| Free cash flow | €8.0M | €6.1M | €13.5M | €6.3M | €4.3M |
| Capital expenditure | −€2.8M | −€6.9M | −€6.1M | −€7.8M | −€6.1M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Brockhaus Technologies | BKHT.DE | €20.70 | €216.27M |
| MPC Münchmeyer Petersen Capital | MPCK.DE | €5.32 | €187.52M |
| Netfonds | NF4.DE | €79.00 | €184.07M |
| Heliad | A7A.DE | €14.05 | €126.62M |
| Laiqon | LQAG.DE | €4.62 | €97.67M |
| Scherzer | PZS.DE | €2.66 | €71.10M |
| ALBIS Leasing | ALG.DE | €3.30 | €69.94M |
| Shareholder Value Beteiligungen | SVE.DE | €79.00 | €53.49M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Blue Cap from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search B7E and buy
Find Blue Cap by name or by its ticker, B7E, and place your order.
Why invest in Blue Cap from India
What Blue Cap does
Blue Cap AG, a private equity firm founded in 2006 and headquartered in Munich, Germany, is dedicated to acquiring and fostering growth in established, mid-market companies. Their investment strategies encompass later-stage growth capital, recapitalizations, and management buyouts or buy-ins. Blue Cap operates in the Asset Management industry within the Financial Services sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Blue Cap stock from India?
Yes. Indian residents and NRIs can buy Blue Cap (B7E) shares directly through Paasa. Blue Cap is listed on XETRA, in the Asset Management industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Blue Cap shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.